ReviewFrontiers in endocrinology2022
Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05933018 (Interconnection Between Night Hyperglycemia and Fatty Liver in Type 1 Diabetes Mellitus), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interconnection Between Night Hyperglycemia and Fatty Liver in Type 1 Diabetes Mellitus
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- The Emerging Potential of Diabetes Technology to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 1 Diabetes: A Narrative Review.Biomedicines · 2026Review
- Integrative gene target mapping, RNA sequencing, in silico molecular docking, ADMET profiling and molecular dynamics simulation study of marine derived molecules for type 1 diabetes mellitus.Molecular diversity · 2026Article
- Metabolic Risk Factors and Clinical Presentations of Metabolic Dysfunction-associated Steatotic Liver Disease Using Data from theJournal of clinical and translational hepatology · 2026Article
- Evaluation of Liver Steatosis and Liver Fibrosis in Patients with Type 1 Diabetes Mellitus Using Non-invasive Scores.Sisli Etfal Hastanesi tip bulteni · 2026Article
- Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes.Diabetes, obesity & metabolism · 2025Article
- Genetic evidence for causal links between type 1 diabetes and autoimmune liver diseases.Diabetology & metabolic syndrome · 2025Article
- Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes.Scientific reports · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes.Journal of clinical medicine · 2025Review
- Prevalence of liver disorders in children and adolescents with type 1 diabetes mellitus.BMC pediatrics · 2025Article
- Article
- Hepatomegaly and Deranged Liver Enzymes in a Patient With Poorly Controlled Type 1 Diabetes Mellitus.JCEM case reports · 2025Article
- Euglycemic Ketoacidosis Postsleeve Gastrectomy in 2 People With Type 1 Diabetes Using Automated Insulin Delivery.JCEM case reports · 2025Article
- Managing obesity in adults with type 1 diabetes.Diabetes research and clinical practice · 2025Review
- The Efficacy of Home-based Resistance Exercise and Game-based Exercise Training on microRNA-21-5p Expression and Non-Alcoholic Fatty Liver Biomarkers in Children with Type 1 Diabetes.Advanced biomedical research · 2025Article
- Role of AMP deaminase in diabetic cardiomyopathy.Molecular and cellular biochemistry · 2024Review
- Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping.World journal of gastrointestinal pathophysiology · 2024Review
- Gut microbiome and NAFLD: impact and therapeutic potential.Frontiers in microbiology · 2024Review
- Relationship between liver and cardiometabolic health in type 1 diabetes.Frontiers in endocrinology · 2024Review
- Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies.International journal of molecular sciences · 2023Review
- Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in the general population with a global prevalence of 25%. It is often associated with metabolic syndrome and type 2 diabetes, as insulin resistance and hyperinsulinemia are known to be favoring factors. Recent studies have described growing incidence of NAFLD in type 1 diabetes (T1D) as well. Although increasing prevalence of metabolic syndrome in these patients seems to explain part of this increase in NAFLD, other underlying mechanisms may participate in the emergence of NAFLD. Notably, some genetic factors are more associated with fatty liver disease, but their prevalence in T1D has not been evaluated. Moreover, oxidative stress, poor glucose control and long-lasting hyperglycemia, as well as exogenous insulin administration play an important role in intrahepatic fat homeostasis. The main differential diagnosis of NAFLD in T1D is glycogenic hepatopathy, which needs to be considered mostly in T1D patients with poor glycemic control. This article aims to review the prevalence and pathophysiology of NAFLD in T1D and open perspectives for clinicians taking care of T1D patients with potential hepatopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.